In spontaneously hypertensive rats, siRNA-mediated blood pressure lowering was rapidly reversed by intravenous angiotensin II or norepinephrine, and gradually reversed by fludrocortisone or high salt.
Do conventional vasopressors raise arterial pressure after angiotensinogen depletion by siRNA in spontaneously hypertensive rats?
Conventional vasopressors and fludrocortisone can effectively reverse the blood pressure-lowering effects of angiotensinogen-targeting siRNA, addressing safety concerns regarding hypovolemia management.
Background A single dose of small interfering RNA (siRNA) targeting liver angiotensinogen eliminates hepatic angiotensinogen and lowers blood pressure. Angiotensinogen elimination raises concerns for clinical application because an angiotensin rise is needed to maintain perfusion pressure during hypovolemia. Here, we investigated whether conventional vasopressors can raise arterial pressure after angiotensinogen depletion. Methods and Results Spontaneously hypertensive rats on a low-salt diet were treated with siRNA (10 mg/kg fortnightly) for 4 weeks, supplemented during the final 2 weeks with fludrocortisone (6 mg/kg per day), the α-adrenergic agonist midodrine (4 mg/kg per day), or a high-salt diet (all groups n=6-7). Pressor responsiveness to angiotensin II and norepinephrine was assessed before and after siRNA administration. Blood pressure was measured via radiotelemetry. Depletion of liver angiotensinogen by siRNA lowered plasma angiotensinogen concentrations by 99.2±0.1% and mean arterial pressure by 19 mm Hg. siRNA-mediated blood pressure lowering was rapidly reversed by intravenous angiotensin II or norepinephrine, or gradually reversed by fludrocortisone or high salt intake. Midodrine had no effect. Unexpectedly, fludrocortisone partially restored plasma angiotensinogen concentrations in siRNA-treated rats, and nearly abolished plasma renin concentrations. To investigate whether this angiotensinogen originated from nonhepatic sources, fludrocortisone was administered to mice lacking hepatic angiotensinogen. Fludrocortisone did not increase angiotensinogen in these mice, implying that the rise in angiotensinogen in the siRNA-treated rats must have depended on the liver, most likely reflecting diminished cleavage by renin. Conclusions Intact pressor responsiveness to conventional vasopressors provides pharmacological means to regulate the blood pressure-lowering effect of angiotensinogen siRNA and may support future therapeutic implementation of siRNA.
Uijl et al. (Mon,) conducted a other in Hypertension. Conventional vasopressors (angiotensin II, norepinephrine, fludrocortisone, high salt) vs. siRNA alone was evaluated on Pressor responsiveness and blood pressure. In spontaneously hypertensive rats, siRNA-mediated blood pressure lowering was rapidly reversed by intravenous angiotensin II or norepinephrine, and gradually reversed by fludrocortisone or high salt.